The European Commission has launched the European Radioisotope Valley Initiative, a new strategic framework intended to strengthen medical-radioisotope production in Europe, guide investment across the supply chain, and reduce dependencies on third countries, particularly Russia.
ERVI sets out five strategic priorities and 10 actions spanning research, industrial investment, market monitoring, international partnerships, and regulation. The initiative follows a feasibility study published in March and builds on the Commission’s existing SAMIRA programme for medical ionising-radiation applications.
More than 10 million procedures using medical radioisotopes are performed in the EU each year, mainly in oncology and cardiology. Europe is already the world’s leading producer and exports around half of its production, but the Commission argues that ageing facilities and dependence on foreign suppliers could weaken that position as global demand increases.
Radioisotope supply has an industrial constraint that most conventional healthcare products do not: radioactive decay starts immediately after production. Many isotopes cannot be stored for long periods, so reactor or accelerator output, processing, radiopharmaceutical manufacture, transport, and hospital scheduling operate within tightly controlled time windows.
That makes outages unusually disruptive. A planned reactor shutdown or an unexpected problem at a processing facility can affect hospitals far beyond the country where the disruption occurs, while transport delays consume part of the product’s useful lifetime rather than merely adding logistics cost.
ERVI’s first priority is research and development. The Commission plans to support next-generation medical radioisotopes, radiopharmaceuticals, and production technologies through a Strategic Research and Innovation Agenda intended to connect scientific programmes more closely with patient and market requirements.
The second priority is more directly industrial. Member states and companies are being encouraged to upgrade existing reactors, construct new production facilities, and invest across the wider radioisotope value chain. The Commission also wants financing mechanisms to combine public and private capital more effectively around projects with long lead times.
Two supply dependencies receive particular attention. ERVI calls for development of EU-based metallic High Assay Low Enriched Uranium capacity and production of stable isotopes that are currently imported from Russia.
Those materials sit upstream of the radiopharmaceutical delivered to a hospital but can still determine whether a production chain operates. Metallic HALEU and stable-isotope feedstocks form part of specialist nuclear and isotope-production supply chains in which substitution can require new qualified processes and suppliers.
The Commission is not proposing complete European self-sufficiency. It explicitly identifies continued cooperation with the UK and United States as important to a resilient metallic-HALEU supply chain, combining localisation of critical capability with diversification among trusted international suppliers.
The third priority concerns market monitoring and forecasting. The Commission plans to build on the European Observatory on the Supply of Medical Radioisotopes to improve visibility of demand, production availability, and future investment needs, while linking that work to newer EU mechanisms dealing with shortages of essential medicines.
Better information matters because radioisotope infrastructure is expensive and slow to replace. Research reactors, accelerators, hot cells, target-processing lines, radioactive-material handling systems, and radiopharmaceutical plants all require specialist engineering, licensing, qualified personnel, and extensive commissioning before commercial or clinical supply can begin.
A company or public authority deciding whether to invest therefore needs some confidence in future demand years before the capacity becomes available. Market monitoring cannot remove that risk, but poor forecasting can leave Europe oscillating between shortages and underused facilities.
International partnerships form ERVI’s fourth strand, with the Commission seeking cooperation on supply diversification, resilience, research, and industrial collaboration. The fifth addresses regulation and transport, including work with the International Atomic Energy Agency and efforts to streamline procedures affecting radiation protection, waste management, and movement of isotopes between member states.
Transport is especially important for short-lived products. A delay at a border or airport can materially reduce usable activity before a shipment reaches its destination, turning regulatory friction into lost manufacturing output.
The strategy also links radioisotopes to the EU’s broader effort to reduce strategic dependencies on Russia. REPowerEU is usually discussed in relation to fuels and electricity, but ERVI shows how similar dependencies can sit inside specialist nuclear supply chains that serve healthcare rather than power generation.
What ERVI does not provide is a single investment budget or a definitive list of new factories. It is a policy and coordination framework designed to steer member states, industry, research programmes, and financing towards identified weak points.
That distinction matters because frameworks do not create isotope capacity by themselves. Reactors still have to be refurbished or built, isotope production established, processing lines qualified, transport routes maintained, and skilled operators retained.
Europe begins from a strong manufacturing position, which makes the initiative less about creating an industry from scratch than preventing an existing one from becoming fragile. The next useful evidence will be the capital projects that follow, because medical-radioisotope resilience is ultimately measured in reliable production schedules and delivered doses rather than another strategy document.
